Key facts
- Dalan’s last known valuation is $14.0M (Jun 2023).
- It has raised $9.4M; the latest was Later Stage VC ($3.0M) in Dec 2025.
- Notable investors include European Innovation Council, Climate Capital, At One Ventures, Good Growth Capital, Prime Movers Lab — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Dalan
- ·The full record, as it builds
Funding rounds
No funding rounds for Dalan are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dalan
Operator of an insect health company intended to provide sustainable approaches to ensure a safe food supply. The company's platform is based on an oral immunization strategy that helps in the food and feed production supply chain to ensure maximum crop yield without any artificial additives or preservatives, and is suitable for organic agriculture, enabling health professionals to protect the world's honeybees from infectious, deadly diseases and ensure a safe food supply.
- Sector
- Healthcare
- HQ
- Athens, GA, United States
- Founded
- 2018
- Employees
- 17
- Website
- dalan.com/
- Ownership
- Privately Held (backing)
Dalan doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dalan shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dalan in its N-PORT filings yet. We sweep new filings monthly.